Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; its reference list is not available; 5 of the 32 sources its claims cite were checked for support.

The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis

Open access

Abstract

Purpose: About 20–25% of patients experience weight regain (WR) or insufficient weight loss (IWL) after bariatric metabolic surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness of adjunct treatment with the GLP-1 receptor agonist semaglutide in non-diabetic patients with WR or IWL after BS. Materials and Methods: Post-bariatric patients without type 2 diabetes (T2D) with WR or IWL (n = 44) were included in the analysis. The primary endpoint was weight loss 3 and 6 months after initiation of adjunct treatment. Secondary endpoints included change in BMI, HbA1c, lipid profile, hs-CRP, and liver enzymes. Results: Patients started semaglutide 64.7 ± 47.6 months (mean ± SD) after BS. At initiation of semaglutide, WR after post-bariatric weight nadir was 12.3 ± 14.4% (mean ± SD). Total weight loss during semaglutide treatment was − 6.0 ± 4.3% (mean ± SD, p < 0.001) after 3 months (3.2 months, IQR 3.0–3.5, n = 38) and − 10.3 ± 5.5% (mean ± SD, p < 0.001) after 6 months (5.8 months, IQR 5.8–6.4, n = 20). At 3 months, categorical weight loss was > 5% in 61% of patients, > 10% in 16% of patients, and > 15% in 2% of patients. Triglycerides (OR = 0.99; p < 0.05), ALT (OR = 0.87; p = 0.05), and AST (OR = 0.89; p < 0.05) at baseline were negatively associated with weight loss of at least 5% at 3 months’ follow-up (p < 0.05). Conclusion: Treatment options to manage post-bariatric excess weight (regain) are scarce. Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients. However, these results need to be confirmed in a prospective randomized controlled trial to close the gap between lifestyle intervention and revision surgery in patients with IWL or WR after BS. Graphical abstract:

Overview

CoChat Summary

TL;DR

In non-diabetic patients with weight regain or insufficient weight loss after bariatric surgery, adjunct semaglutide 0.5 mg once-weekly was associated with significant weight loss at 3 and 6 months. The authors conclude this implies a clear benefit but state results need confirmation in a prospective randomized controlled trial.

Key findings

  • Among 44 patients, semaglutide was started 64.7 ± 47.6 months after bariatric surgery; weight regain after post-bariatric nadir was 12.3 ± 14.4%. Total weight loss was −6.0 ± 4.3% at 3 months (n = 38, p < 0.001) and −10.3 ± 5.5% at 6 months (n = 20, p < 0.001).
  • At 3 months, categorical weight loss was >5% in 61%, >10% in 16%, and >15% in 2% of patients; at 6 months, >5% in 85%, >10% in 45%, and >15% in 5%.
  • No significant differences in weight loss were found between SG and RYGB at 3 months (p = 0.7) or 6 months (p = 0.8), or between WR and IWL groups. Female patients had greater weight loss at 3 months (−7.10 ± 3.95%) than male patients (−2.44 ± 3.77%; p = 0.005).
  • Baseline triglycerides (OR = 0.99; p < 0.05), ALT (OR = 0.87; p = 0.05), and AST (OR = 0.89; p < 0.05) were negatively associated with ≥5% weight loss at 3 months. HbA1c, lipids, hs-CRP, and liver enzymes showed no significant change; side effects included nausea in two patients during the first 2 weeks and one transient lipase increase.

Methods

  • Retrospective analysis of 44 adult non-diabetic post-bariatric patients with WR or IWL after SG or RYGB, treated between 2020 and 2022 at a certified obesity outpatient clinic; 9 of 53 initial patients were excluded.
  • Patients received semaglutide 0.25 mg/week for the first 4 weeks, then 0.5 mg/week thereafter according to tolerability; data were allocated to baseline, 1 month (n = 44), 3 months (n = 38), and 6 months (n = 20).
  • Analyses included descriptive statistics, Student’s t-test, chi-square, one-way ANOVA with Dunnett’s test, two-way ANOVA with Šídák’s test, and univariate logistic regression for ≥5% weight loss at 3 months; p < 0.05 was significant.

Limitations

  • The paper states this was a retrospective analysis of a small number of patients lacking a control group, with only 20 patients at 6 months’ follow-up, and that differences in dose titration and time point of treatment initiation may have impacted variability in weight loss.
  • Evident from the text: it was a single-center observational study using off-label semaglutide at a maximum dose of 0.5 mg once-weekly, so causality cannot be established and results may not generalize to the later-approved 2.4 mg dose.
  • Evident from the text: some subgroup results, including sex differences and WR versus IWL comparisons, are reported as “data not shown.”

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s11695-022-06211-9

Cites

Statistics

Nothing to recompute.

Figures

Fig. 1 Weight loss over time following adjunct treatment with semaglutide once-weekly by type of surgery. SG, sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; FU, follow-up; N, number of individuals. Results are expressed as means and standard deviation. *Significantly different from baseline regardless of surgical group (p < 0.001)
Fig. 1 Weight loss over time following adjunct treatment with semaglutide once-weekly by type of surgery. SG, sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; FU, follow-up; N, number of individuals. Results are expressed as means and standard deviation. *Significantly different from baseline regardless of surgical group (p < 0.001)CC BY · PubMed Central
Fig. 2 Percentages of patients who reached weight loss of at least 5%, 10%, 15%, and 20%, respectively, following adjunct treatment with semaglutide once-weekly for 1, 3, and 6 months. FU, follow-up; N, number of individuals
Fig. 2 Percentages of patients who reached weight loss of at least 5%, 10%, 15%, and 20%, respectively, following adjunct treatment with semaglutide once-weekly for 1, 3, and 6 months. FU, follow-up; N, number of individualsCC BY · PubMed Central

Verification

Claims the paper makes

4 Valid · 0 Not valid · 14 Not checked · 39 Own results and interpretations

30 more claims

Create a free account to see all 57 claims and to verify the 27 references still open.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 34 · Cited by 92

Research works printed but not linked: 1

  1. Dushay J, Eleftheria M;, Flier M, et al. Patterns and predictors of weight loss with exenatide treatment in overweight and obese women. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; 2020 [cited 2021 Dec 28];2020.06.11.20128645. Available from: https://www.medrxiv.org/content/https://doi.org/10.1101/2020.06.11.20128645v1 · doi:10.1101/2020.06.11.20128645v1

Metadata

Authors
Lautenbach, A., Wernecke, M., Huber, T. B., Stoll, F., Wagner, J., Meyhöfer, S. M., Meyhöfer, S., & Aberle, J.
Affiliations
  • University Medical Center Hamburg-Eppendorf (DE)
  • German Center for Diabetes Research (DE)
Corresponding author
Lautenbach, Anne
Venue
Obesity Surgery
Published
2022-07-25
Volume
32
Issue
10
Pages
3280-3288
ISSN
  • 0960-8923 (ISSN-L)
  • 1708-0428
OpenAlex
W4287833463
Cited by
92
References
34
Citations by year
2026: 19 · 2025: 33 · 2024: 23 · 2023: 15 · 2022: 2
FWCI
17.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Obesity Surgery (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Universitätsklinikum Hamburg-Eppendorf (UKE)
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Body Contouring and Surgery
Keywords
semaglutide, GLP-1 receptor agonists
MeSH terms
Glucagon-Like Peptide-1 Receptor, Semaglutide, C-Reactive Protein, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Lipids, Obesity, Morbid, Prospective Studies, Retrospective Studies, Triglycerides, Weight Gain, Weight Loss, Bariatric Surgery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis. https://app.cochat.ai/papers/10.1007/s11695-022-06211-9
The paper
Lautenbach, A., Wernecke, M., Huber, T. B., Stoll, F., Wagner, J., Meyhöfer, S. M., Meyhöfer, S., & Aberle, J. (2022). The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis. Obesity Surgery. https://doi.org/10.1007/s11695-022-06211-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.